US drugmaker Eli Lilly (NYSE: LLY) was trading more than 3% lower by the early afternoon on Thursday after presenting its financial results for the second quarter of 2022, alongside its projections for the rest of the year.
Lilly missed analysts’ estimates with its revenue and earnings figures for the quarter.
The company’s revenue total of $6.49 billion missed the consensus estimate of $6.84 billion and was 4% lower than the same period of 2021.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze